Comparative Pharmacology
Head-to-head clinical analysis: RENO 30 versus RENOCAL 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENO 30 versus RENOCAL 76.
RENO-30 vs RENOCAL-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures.
Contains iothalamate meglumine, an ionic high-osmolar contrast medium that absorbs X-rays, thereby enhancing vascular and tissue contrast during radiographic procedures. It functions by increasing the attenuation of X-rays in blood and tissues where it distributes.
Adults: 30 mL (30 g iodine) intravenously as a single dose for imaging procedures; may repeat once if needed.
Intravenous: 50-100 mL of a 37% iodine-containing solution (approximately 14-28 g iodine) administered as a slow intravenous injection over 1-2 minutes, or as an intravenous infusion over 10-30 minutes, typically not exceeding 4.5 mL/kg body weight.
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life ranges from 1.2 to 2.5 hours in patients with normal renal function. In patients with severe renal impairment, half-life may be prolonged up to 20 hours.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily renal excretion via glomerular filtration. Approximately 95% of administered dose is excreted unchanged in urine within 24 hours. Less than 5% undergoes biliary/fecal elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent